Drug Profile
H7N9 influenza vaccine - Shanghai Institute Of Biological Products
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Shanghai Institute of Biological Products
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in China (Parenteral)
- 20 Dec 2017 Shanghai Institute Of Biological Products in collaboration with Henan Center for Disease Control and Prevention plans a phase I/II trial for Influenza-A virus H7N9 subtype (Prevention) in December 2017 (NCT03369808)
- 01 Dec 2017 Preclinical trials in Influenza-A virus H7N9 subtype in China (Parenteral) (NCT03369808)